119 related articles for article (PubMed ID: 22613190)
1. Chemoimmunotherapy with bendamustine hydrochloride and alemtuzumab demonstrates synergism in T-prolymphocytic leukemia.
Yong HX; Linn YC; Ong KH; Tan D
Leuk Res; 2012 Aug; 36(8):e163-5. PubMed ID: 22613190
[No Abstract] [Full Text] [Related]
2. Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia.
Sohani AR; Ferry JA; Chang PS; Abramson JS
J Clin Oncol; 2010 Feb; 28(5):e69-72. PubMed ID: 19917859
[No Abstract] [Full Text] [Related]
3. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
[TBL] [Abstract][Full Text] [Related]
4. T-cell prolymphocytic leukemia.
Khot A; Dearden C
Expert Rev Anticancer Ther; 2009 Mar; 9(3):365-71. PubMed ID: 19275513
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine is effective in T-cell prolymphocytic leukaemia.
Herbaux C; Genet P; Bouabdallah K; Pignon JM; Debarri H; Guidez S; Betrian S; Leleu X; Facon T; Morschhauser F; Damaj G; Cazin B; Ysebaert L
Br J Haematol; 2015 Mar; 168(6):916-9. PubMed ID: 25316212
[No Abstract] [Full Text] [Related]
6. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.
Krishnan B; Else M; Tjonnfjord GE; Cazin B; Carney D; Carter J; Ketterer N; Catovsky D; Ethell M; Matutes E; Dearden CE
Br J Haematol; 2010 Jun; 149(6):907-10. PubMed ID: 20201944
[No Abstract] [Full Text] [Related]
7. Primary refractory T-cell prolymphocytic leukaemia treated with daily administration of Alemtuzumab plus high-dose methylprednisolone.
Renaudon-Smith E; Gribben JG; Agrawal SG
Eur J Haematol; 2014 Apr; 92(4):360-1. PubMed ID: 24329558
[No Abstract] [Full Text] [Related]
8. Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation?
Herling M
Eur J Haematol; 2015 Mar; 94(3):191-2. PubMed ID: 25712069
[No Abstract] [Full Text] [Related]
9. A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
Paul RN; Alizadeh L; Ajayi OI; Karpurapu H; Ganesan C; Taddesse-Heath L; Aggarwal A
Acta Haematol; 2012; 127(4):235-43. PubMed ID: 22517037
[TBL] [Abstract][Full Text] [Related]
10. Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature.
Abbi KK; Rizvi SM; Sivik J; Thyagarajan S; Loughran T; Drabick JJ
Leuk Res; 2010 Jul; 34(7):e154-6. PubMed ID: 20362332
[No Abstract] [Full Text] [Related]
11. T-cell prolymphocytic leukemia.
Dearden CE
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S239-43. PubMed ID: 19778847
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia.
Alsawah F; Benitez L; Choi S; Marini B; Perissinotti A; Skyles A; Burke P; Pettit K; Crouch A; Fox H; Bixby D
Blood Adv; 2019 Nov; 3(21):3333-3336. PubMed ID: 31698446
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
Boyd K; Dearden CE
Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
[TBL] [Abstract][Full Text] [Related]
14. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
Cao TM; Coutre SE
Hematology; 2003 Feb; 8(1):1-6. PubMed ID: 12623420
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Presentation of T-Cell Prolymphocytic Leukemia Mimicking Dermatomyositis.
Ingrasci G; Diaz-Perez J; Verne S; Romanelli P; Yosipovitch G
Am J Dermatopathol; 2021 Jul; 43(7):521-524. PubMed ID: 33606377
[TBL] [Abstract][Full Text] [Related]
16. T-cell chronic lymphocytic leukemia/T-prolymphocytic leukemia: Experience with single agent bendamustine.
Thota NK; Sadashivudu G; Gandhi LV; Pragnya C; Roshni TP; Raghunadharao D
Indian J Cancer; 2015; 52(2):193-4. PubMed ID: 26853400
[No Abstract] [Full Text] [Related]
17. [Current concepts in chronic lymphocytic leukemia. Better chances for young patients].
Hallek M; Bergmann M; Goede V; Fingerle-Rowson G; Schweighofer C; Schmitt B; Wendtner CM; Emmerich B
MMW Fortschr Med; 2003 Jul; 145(27-28):46-9. PubMed ID: 14587189
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia.
Lu L; Peters J; Roome C; Stein K
Int J Technol Assess Health Care; 2012 Jul; 28(3):241-8. PubMed ID: 22980700
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.
Hasanali ZS; Saroya BS; Stuart A; Shimko S; Evans J; Vinod Shah M; Sharma K; Leshchenko VV; Parekh S; Loughran TP; Epner EM
Sci Transl Med; 2015 Jun; 7(293):293ra102. PubMed ID: 26109102
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route.
Dearden CE; Khot A; Else M; Hamblin M; Grand E; Roy A; Hewamana S; Matutes E; Catovsky D
Blood; 2011 Nov; 118(22):5799-802. PubMed ID: 21948296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
